No description yet.
New York, NYFounded 2020
1 source · checked 1 time, last 3d ago
The filing reports an offering and sales but does not label a financing stage or name investors.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Form D (equity) [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $5M | 2026-10-23 | not stated | No recent discussion |
1 source · checked 1 time, last 3d ago [ VERIFIED ] read against 1 source The filing reports an offering and sales but does not label a financing stage or name investors.; not on the page it cites, so not applied: date [ BUILT WITH ]·[ SEARCH ]from a Form D filing·[ SCRAPE ]1 page read: sec.gov·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
Graviton BioScience develops selective ROCK2 and other therapies for people with fibrotic, autoimmune, CNS, and other serious diseases.
Checked against 12 sources 3d ago
None named.
Also named as backers in company research: Sanofi, Ovid Therapeutics, Enavate Sciences, Cormorant Asset Management, Pontifax Venture Capital